Trial Profile
Phase II Trial of 5-FU, Leucovorin, Gemcitabine, and Cisplatin for Adenocarcinomas of the Urothelial Tract and Urachal Remnant
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Gemcitabine (Primary)
- Indications Adenocarcinoma; Bladder cancer; Urogenital cancer
- Focus Therapeutic Use
- 29 Oct 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 29 Oct 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 17 Apr 2023 Planned End Date changed from 15 Dec 2022 to 31 Dec 2023.